Web2 set 2014 · Further studies demonstrated that binding to DRAK2 inhibits SRSF6 phosphorylation by the SRSF kinase SRPK1 and regulates alternative splicing of mitochondrial function-related genes. Web17 nov 2024 · Dalamaga M., Liu J. DRAK2-SRSF6-regulated RNA alternative splicing is a promising therapeutic target in NAFLD/NASH. Metabol Open. 2024; 13 [ Europe PMC free article ] [ Abstract ] [ Google Scholar ]
Author Page for Jing-Ya Li :: SSRN
WebSRSF6, serine and arginine rich splicing factor 6 Vertebrate Orthologs 4 Vertebrate Orthology Source. Alliance of Genome ... J:325189 Li Y, et al., DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing. Cell Metab. 2024 Oct 5;33(10):2004-2024.e9 ... WebDRAK2-SRSF6-regulated RNA alternative splicing is a promising therapeutic target in NAFLD/NASH. Maria Dalamaga, Junli Liu. Article 100157 Download PDF; select article Noninvasive assessment of fibrosis among patients … lightning flow salesforce
DRAK2-SRSF6-regulated RNA alternative splicing is a promising ...
WebDrak2 Aggravates Nonalcoholic Fatty Liver Disease Progression Through SRSF6-Associated RNA Alternative Splicing Number of pages: 58 Posted: 24 Feb 2024 Yufeng Li , Junyu Xu , Hua Bian , Yuting Lu , Honghong Wu , Maoqian Xiong , Lin Yang , Yafei Chang , Xinwen Zhang , Jie Tang , Fan Yang , Lei Zhao , Jing Li , Xin Gao , Ming-Feng Xia , … Web13 gen 2024 · Europe PMC is an archive of life sciences journal literature. This website requires cookies, and the limited processing of your personal data in order to function. Web22 ott 2024 · On October 5, 2024, the Shanghai Institute of Materia Medica Li Jingya and Tan Minjia's research team, together with the Gao Xin/Xia Mingfeng team of Zhongshan Hospital of Fudan University Affiliated Hospital, published the title "DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6 on Cell Metabolism . lightning flow パナソニック